
1. pharmacogenomics. 2017 oct;18(15):1393-1400. doi: 10.2217/pgs-2017-0077. epub
2017 oct 4.

slco1a2, slco1b1 slco2b1 polymorphisms influences chloroquine primaquine 
treatment plasmodium vivax malaria.

sortica va(1), lindenau jd(1), cunha mg(2), ohnishi md(3), r ventura am(3),
ribeiro-dos-santos âk(4), santos se(4), guimarães ls(5), hutz mh(1).

author information: 
(1)departamento de genética, universidade federal rio grande sul, porto
alegre, rs, brazil.
(2)laboratório de microbiologia e imunologia, universidade federal para,
belém, pa, brazil.
(3)programa de ensaios clínicos em malária, instituto evandro chagas, sistema de 
vigilância sanitária, ministério da saúde, ananindeua, pa, brazil.
(4)laboratório de genética humana e médica, universidade federal pará, belém, 
pa, brazil.
(5)unidade de bioestatística, grupo de pesquisa e pós graduação, hospital de
clínicas de porto alegre, porto alegre, rs, brazil.

aim: association transporters gene polymorphisms with
chloroquine/primaquine malaria treatment response investigated brazilian
population.
patients & methods: totally, 164 plasmodium vivax malaria infected patients 
included. generalized estimating equations performed determine gene
influences parasitemia and/or gametocytemia clearance treatment time.
results: significant interaction slco2b1 genotypes treatment over
time parasitemia clearance rate day 2 observed (p fdr = 0.002).
slco1a2 slco1b1 gene treatment time interactions associated with
gametocytemia clearance rate (p fdr = 0.018 p fdr = 0.024). abcb1, abcc4 
slco1b3 associated treatment response.
conclusion: present work presents first pharmacogenetic report an
association chloroquine/primaquine responses oatp transporters.

doi: 10.2217/pgs-2017-0077 
pmcid: pmc7099631
pmid: 28975866  [indexed medline]

